

Global risk radar

Global trade: Playing with the tipping point

30 August 2019

Chief Investment Office, WM

Luca Henzen, Analyst, luca.henzen@ubs.com; **Brian Rose**, Senior Economist Americas; **Philip Wyatt**, Economist, philip.wyatt@ubs.com; **Dirk Effenberger**, Head Investment Risk, Chief Investment Office GWM, dirk.effenberger@ubs.com; **Clemence Rusek**, Analyst, clemence.rusek@ubs.com; **Yifan Hu**, Regional CIO and Chief China Economist, yifan.hu@ubs.com; **Jason Draho**, Head Asset Allocation Americas

This publication series helps investors to identify and assess global financial market risks and their investment implications.

At a glance

- Tensions between US and China have recently escalated once more following President Trump's decision to increase tariffs on US imports from China.
- In our base case, we expect the latest round of tariffs to be implemented and estimate that this will take around 0.3ppt off US growth over the next 12 months. In our downside scenario, we see the risk of a US recession rising significantly as a result of additional US sanctions such as higher tariffs on sensitive goods from China or the imposition of duties on car imports.
- While we still believe that a US recession is not imminent, risks are clearly tilted to the downside. We have recently trimmed our equity exposure, leaving us underweight to stocks overall. Instead, with rates likely to stay lower for longer, we look for income-enhancing opportunities.



Source: iStock

Over the past weeks, the trade conflict between the US and China has unfolded in a series of announcements, countermeasures, bold statements, and reversals. After regretting not raising tariffs on Chinese goods further, US President Trump quickly switched to renewed optimism for a trade deal (see Fig. 1). Predicting the next moves in the US-China conflict has become challenging. Overall, we expect tensions will remain elevated and that currently proposed tariffs will be implemented. However, we don't rule out a worsening of the situation over the next six to 12 months.

Financial markets have been closely following the recent developments in the trade dispute. The VIX index – a proxy for market risk and investor sentiment – has jumped in August to levels last seen at the end of 2018. In the meantime, bond yields have fallen considerably and, for the first time since the financial crisis, the spread between 2- and 10-year Treasury yields has become negative, a development that has in the past anticipated recessions.

Related reports:

- Global financial markets: "Reducing equity exposure," 26 August
- UBS House View CIO Alert: "Lowering risk in portfolios on rising trade tensions," 25 August
- Global financial markets: "Cycle scenarios: How can investors position?," 19 August
- UBS Global Risk Radar: "US-China trade: Further from the truce," 9 August

Despite the rising risks, we still believe the US can avoid a recession in 2020. Nevertheless, we acknowledge that markets are increasingly being driven by trade news – even more than monetary policy. With high uncertainty over the outlook for the trade dispute, we prefer to limit our exposure to stock markets. In our tactical asset allocation, we are modestly underweight equities and favor carry strategies, which should benefit from central bank easing in a low-growth environment.

Tariff escalations intensify

The temporary ceasefire resulting from the G20 summit ended in the first week of August, when President Trump decided to levy a 10% tariff on USD 300bn of Chinese goods. Since this announcement, the dispute has quickly alternated between softening and tit-for-tat moves (see Fig. 1).

The step up in the pace of retaliation and the US pledge to increase tariff above 25% rate – a level that many believed to be a ceiling in punitive levies – have marked a shift toward a higher level of escalation.

We believe that Beijing has also changed its stance on trade. Since the breakdown of negotiations in May, China has been even more reluctant to offer unilateral concessions and has embraced the idea that a resolution of the trade conflict would not mitigate the tensions with the US. In our view, the rivalry between the two nations has gone far beyond trade, extending to other fronts including technological leadership and geopolitical supremacy.

At present, we still believe that the negotiations scheduled for early September will take place. Both sides are poised to head back to the table, but the risk that the global economy has been irreversibly dented from the latest tariff escalation is very high.

Our scenarios

Base case (45% chance): Prolonged trade tensions

In our baseline scenario, we expect the latest round of tariffs to be implemented. We estimate that this will take around 0.3ppt off US growth over the next 12 months. We do not believe this will be enough to tip the economy into recession, but we cannot rule out the possibility that sentiment will turn down more than we forecast. We expect China's response to be measured (see Table 1), although we cannot exclude further US sanctions to the extent that the US economy is not irremediably impaired.

China's response is likely to include mild retaliation because in the end it continues to engage in talks and we think fundamentally seeks a deal. Under this scenario China's GDP growth suffers by attrition and could slow to 5.8%-6% next year. We see the CNY depreciating further, perhaps as far as 7.4 in the next 3-6 months.

Currently, we expect the US Federal Reserve to cut interest rates three more times in the next 12 months. A decision to ease monetary policy further could support Trump in his aggressive trade policy agenda and feed a fresh rounds of tariffs.

Fig. 1: US-China trade dispute since May 2019 5 May 2019: Trump raises tariff on USD 200bn of Chinese imports from 10% to 25% 13 May 2019: China announces an incrreases to 5-25% on USD 60bn of US products 16 May 2019: Huawei and affiliates added to the US Commerce Department's entity list 17 May 2019: US Trade Representative announces preliminary tariff list on USD 300bn Chinese products 31 May 2019: China introduces its 'unreliable entity list' 2 Jun 2019: White paper on China's position in the trade talks with US 29 Jun 2019: G20 meeting and agreement on a ceasefire 1 Aug 2019: Trump announces tariffs on USD 300bn Chinese imports 5 Aug 2019: US Treasury designates China as currency manipulator after USDCNY broke above 7 14 Aug 2019: US delays part of tariffs on USD 300bn Chinese imports from 1 Sep to 15 Dec 23 Aug 2019: China unveils tariffs on USD 75bn of US goods and reinstated 25% duty on imports of US cars and car parts 23 Aug 2019: US raises all tariffs on Chinese imports by 5% 26 Aug 2019: Trump claims serious talks to begin with China over trade negotiations 29 Aug 2019: China indicates it won't retaliate immediately against latest US tariff increase

Source: UBS, as of 30 August 2019

Table 1: Possible measured responses from China

- · Moderately increasing tariffs on current US imports
- \cdot Curbing further US imports such as agricultural goods, aircraft, crude oil, Liquified Natural Gas (LNG)
- · Discouraging travel to the US
- \cdot Allowing managed depreciation of the CNY potentially up to 7.4
- Releasing an "Unreliable Entity List" for US companies, similar to the US Entity List
- · Curbing imports of US services, including tourism and education, IP products including movies and CDs, and professional services (e.g. legal, accounting, and financial services)

Source: UBS, as of 30 August 2019

In our view, the outlook for a deal before the US election remains weak. Nevertheless, we still believe that the US administration will try to avoid increasing the risk of a recession unnecessarily ahead of the US presidential election next year. This should ultimately dissuade the White House from significantly increasing tariffs on Chinese goods.


Downside scenario (35% chance): Escalation leading to a US recession

In our risk case, we see the chances of a US recession and a global economic downturn caused by trade sanctions rising dramatically. The recent escalation has already raised this probability, and so defining a line in the sand to call for an end of the current cycle is harder. However, we think 35%+ tariffs on most goods could be the danger zone, depending on policy offsets. In addition, there are lags where the impact of the latest round of tariffs may only be felt next year. Front-loading of purchases may create the illusion of continued economic strength. Secondary effects including higher uncertainty on business confidence and the full impact of supply chain shifts may also take time to show up. We prefer therefore to define actions on the trade front that would give us a fair confidence to call the end of the longest US expansion on record over our tactical investment horizon.

- More tariffs: In a situation where the US administration decides to increase the tariff rate on Chinese imports to a level that would irreparably hurt margins of US companies, lower earnings would quickly take a toll on employment. We believe that a step-up to 25%+ of the tariff rate on the consumer electronics (currently set at 15%) or an outright increase of the average tariff rate on China from the current 23.3% (see Fig. 2) to more than 35% would force companies to materially cut investment and ultimately jobs. China's response would likely include yet greater tariffs on US agriculture and key services products such as banking, tourism and education, IP-entertainment/leisure products. On the policy side, support would step up to avoid GDP growth sinking too far below 5.5% with a combination of greater PBoC lending facilities, 200bp+ of general RRR cuts, more than 20bp of medium-term lending facility (MLF) interest rate cuts and CNY 4tn+ of local government bonds issued. CNY depreciation would accompany this and a move weaker than 7.5 may be unavoidable. A more serious breakdown of diplomatic relations could trigger US Treasury bond sales.
- Technology escalation: So far, the US Department of Commerce has granted a temporary delay to an import ban against Chinese telecom giant Huawei. The US administration could decide to escalate on the tech front by immediately restricting US companies trading with Huawei or including more Chinese companies in the Entity List, perhaps extending into artificial intelligence (AI) and biotech, effectively blocking them from receiving US tech products. China's response may mirror such a move and lengthen its own list of US companies on the Unreliable list, imposing on them a higher cost of doing business. In such a case China would have to live with much reduced access to US tech products, and this over time would depress China's growth trajectory, with 2020 growth perhaps 50bps slower than our base case of a 5.8%-6% range.

Fig. 2: Bilateral tariffs have crossed the 20% level on both sides

Average tariff rate on imports (weights based on 2017 trade data)



Source, Deutsche Bank, UBS, as of 30 August 2019

- Auto tariffs: A final decision on the US investigation into auto imports is expected by mid-November. The US administration has, so far, refrained from levying duties on auto imports. Despite large consensus against these tariffs from the US Congress and business community, Trump has recently indicated that auto tariffs remain a possibility. We believe that a 25% tariff an all US auto and auto component imports would harm major auto exporters such as Germany and Japan while also hurting the US auto industry, and could make the global economy stumble. While the US and Japan may soon sign a new trade agreement that would avert US sanctions against Japanese cars, trade talks with the EU have yet to start officially after the European Commission formalized the trade negotiating directives in April. In the meantime, the EU finalized a list of US goods that would be hit with retaliatory tariffs, should President Trump follow through on his threat.
- Other sanctions: Recently, US president Trump ordered "American companies to immediately start looking for an alternative to China", threatening to invoke the US International Emergency Economic Powers Act (IEEPA). Such a move would impair US investment in China and make it difficult to do business with Chinese entities. In such case, US firms would be heavily encouraged to relocate and bear the costs of shifting their supply chain.

Upside scenario (20% chance): De-escalation before the US election

In our de-escalation scenario, we expect a significant improvement in US-China trade relations before the US election next year. There are already signs that some of President Trump's core supporters in the 2016 election are losing patience with the trade war, most notably farmers. The President can also ill afford a sharp slowdown in economic growth going into the election. If risks for a second term re-election should increase, Trump could decide to step-back from his aggressive negotiating tactic with China and try to reach a preliminary deal to please markets and promote his image of great deal-maker.

Although China indicated its preference for rolling back tariffs instead of escalating further, we believe Beijing will only accept an agreement, if Washington would ease restrictions against Huawei and other Chinese tech companies. Given the growing bipartisan consensus in the US to limit the Chinese technological ascent, we assign a low probability that such scenario could materialize.

Table 2: Summary of new CIO scenarios for US-China trade

Scenario	Probability (6m view)	Likely path	GDP impact relative to baseline (12m)	Fed response	US recession risk (2020)	Expected market performance (6m)
De-escalation before the US election	20%	 ✓ Some roll-out of currently pledged or already implemented tariffs ♦ High-level talks resume, giving room for further de-escalation 	+25bps +10 to +20bps	-25-50bps	20%	Global equities: 0% to 10% EURUSD: ≤ 1.12 USDCNY: 6.8-7.0 Gold: \$1,400/oz. Oil: \$65-\$75/bbl.
Prolonged trade tensions	45%	US and China latest tariff pledges come into effect as announced Uncertainty continues, further tariffs up to 35% and non-tariff escalation is possible	Baseline (1.75%) Baseline (5.8-6%)	-75-100bps	30%	Global equities: -5% to 0% EURUSD: 1.13-1.18 USDCNY: 7.0-7.4 Gold: \$1,550-\$1,650/oz. Oil: \$55-\$70/bbl.
Escalation leading to a US recession	35%	X 35%+ tariffs on all Chinese goods, and /or auto tariffs, technology escalation High probability of a global economic downturn	-100bps -30 to -50 bps	>-100bps	≥50%	Global equities: -15% to -20% EURUSD: 1.18 USDCNY: 7.4-7.6 Gold: \$1,700/oz. Oil: \$40-\$50/bbl.

^{*} Impact on official headline GDP growth in China, including offsetting effects of countercyclical policy measures by Chinese authorities.

Source: UBS, as of 30 August 2019

Investment conclusions

We recently adjusted our portfolio recommendation to reflect rising risk that the trade conflict could cause more damage to an already weak global economy. While we removed our overweight to equities versus bonds, we have not positioned for a strong equity sell-off, as central banks are in easing mode and fiscal stimulus is also on the horizon. We continue to take risk on income-enhancing strategies, which benefit from central easing as global growth slows.

In our upside scenario, risk assets would appreciate and safe bond yields rise. However, the extent of a risk-on rally would primarily depend on the degree of de-escalation and the amount of central bank policy easing. For global equities we would expect return between 0% and 10% while the USDCNY could potentially dip back below 7.

Our downside scenario would significantly increase the risk of a recession in the US next year. Ultimately, this would put markets from a late cycle stage to end of cycle territory with more severe repercussion for risk asset classes. We would expect global equities to experience a drawdown of 15-20%, with sector exposed to the trade conflict (e.g. industrials or materials) suffering more than defensive sectors such as consumer staples and health care – two sectors which we also like in our base case scenario. Safe-haven currencies such as the Swiss franc and the Japanese yen would appreciate alongside gold, which would likely exceed our target of USD 1,600 oz in six months. The USDCNY could reach 7.6, but a dovish enough Fed would prevent further upside in our view.

For more details on the investment implications of "end-of-cycle scenario" please refer to our report "Cycle scenarios: How can investors position?" from 19 August.

Disclaimer

UBS Chief Investment Office's ("CIO") investment views are prepared and published by the Global Wealth Management business of UBS Switzerland AG (regulated by FINMA in Switzerland) or its affiliates ("UBS").

The investment views have been prepared in accordance with legal requirements designed to promote **the independence of investment research**.

Generic investment research - Risk information:

This publication is **for your information only** and is not intended as an offer, or a solicitation of an offer, to buy or sell any investment or other specific product. The analysis contained herein does not constitute a personal recommendation or take into account the particular investment objectives, investment strategies, financial situation and needs of any specific recipient. It is based on numerous assumptions. Different assumptions could result in materially different results. Certain services and products are subject to legal restrictions and cannot be offered worldwide on an unrestricted basis and/or may not be eligible for sale to all investors. All information and opinions expressed in this document were obtained from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to its accuracy or completeness (other than disclosures relating to UBS). All information and opinions as well as any forecasts, estimates and market prices indicated are current as of the date of this report, and are subject to change without notice. Opinions expressed herein may differ or be contrary to those expressed by other business areas or divisions of UBS as a result of using different assumptions and/or criteria.

In no circumstances may this document or any of the information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes (i) valuation or accounting purposes; (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or (iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees. By receiving this document and the information you will be deemed to represent and warrant to UBS that you will not use this document or otherwise rely on any of the information for any of the above purposes. UBS and any of its directors or employees may be entitled at any time to hold long or short positions in investment instruments referred to herein, carry out transactions involving relevant investment instruments in the capacity of principal or agent, or provide any other services or have officers, who serve as directors, either to/for the issuer, the investment instrument itself or to/for any company commercially or financially affiliated to such issuers. At any time, investment decisions (including whether to buy, sell or hold securities) made by UBS and its employees may differ from or be contrary to the opinions expressed in UBS research publications. Some investments may not be readily realizable since the market in the securities is illiquid and therefore valuing the investment and identifying the risk to which you are exposed may be difficult to quantify. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, divisions or affiliates of UBS. Futures and options trading is not suitable for every investor as there is a substantial risk of loss, and losses in excess of an initial investment may occur. Past performance of an investment is no guaran

Tax treatment depends on the individual circumstances and may be subject to change in the future. UBS does not provide legal or tax advice and makes no representations as to the tax treatment of assets or the investment returns thereon both in general or with reference to specific client's circumstances and needs. We are of necessity unable to take into account the particular investment objectives, financial situation and needs of our individual clients and we would recommend that you take financial and/or tax advice as to the implications (including tax) of investing in any of the products mentioned herein.

This material may not be reproduced or copies circulated without prior authority of UBS. Unless otherwise agreed in writing UBS expressly prohibits the distribution and transfer of this material to third parties for any reason. UBS accepts no liability whatsoever for any claims or lawsuits from any third parties arising from the use or distribution of this material. This report is for distribution only under such circumstances as may be permitted by applicable law. For information on the ways in which CIO manages conflicts and maintains independence of its investment views and publication offering, and research and rating methodologies, please visit www.ubs.com/research. Additional information on the relevant authors of this publication and other CIO publication(s) referenced in this report; and copies of any past reports on this topic; are available upon request from your client advisor.

Important Information about Sustainable Investing Strategies: Incorporating environmental, social and governance (ESG) factors or Sustainable Investing considerations may inhibit the portfolio manager's ability to participate in certain investment opportunities that otherwise would be consistent with its investment objective and other principal investment strategies. The returns on a portfolio consisting primarily of ESG or sustainable investments may be lower than a portfolio where such factors are not considered by the portfolio manager. Because sustainability criteria exclude some investments, investors may not be able to take advantage of the same opportunities or market trends as investors that do not use such criteria. Companies may not necessarily meet high performance standards on all aspects of ESG or sustainable investing issues; there is also no guarantee that any company will meet expectations in connection with corporate responsibility, sustainability, and/or impact performance.

Distributed to US persons by UBS Financial Services Inc. or UBS Securities LLC, subsidiaries of UBS AG. UBS Switzerland AG, UBS Europe SE, UBS Bank, S.A., UBS Brasil Administradora de Valores Mobiliarios Ltda, UBS Asesores Mexico, S.A. de C.V., UBS Securities Japan Co., Ltd, UBS Wealth Management Israel Ltd and UBS Menkul Degerler AS are affiliates of UBS AG. UBS Financial Services Incorporated of Puerto Rico is a subsidiary of UBS Financial Services Inc. accepts responsibility for the content of a report prepared by a non-US affiliate when it distributes reports to US persons. All transactions by a US person in the securities mentioned in this report should be effected through a US-registered broker dealer affiliated with UBS, and not through a non-US affiliate. The contents of this report have not been and will not be approved by any securities or investment authority in the United States or elsewhere. UBS Financial Services Inc. is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule") and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule.

External Asset Managers / External Financial Consultants: In case this research or publication is provided to an External Asset Manager or an External Financial Consultant, UBS expressly prohibits that it is redistributed by the External Asset Manager or the External Financial Consultant and is made available to their clients and/or third parties.

Austria: This publication is not intended to constitute a public offer under Austrian law. It is distributed only for information purposes to clients of UBS Europe SE, Niederlassung Österreich, with place of business at Wächtergasse 1, A-1010 Wien. UBS Europe SE, Niederlassung Österreich is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Austrian Financial Market Authority (Finanzmarktaufsicht), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. Bahrain: UBS is a Swiss bank not licensed, supervised or regulated in Bahrain by the Central Bank of Bahrain and does not undertake banking or investment business activities in Bahrain. Therefore, clients have no protection under local banking and investment services laws and regulations. Brazil: This publication is not intended to constitute a public offer under Brazilian law or a research analysis report as per the definition contained under the Comissão de Valores Mobiliários ("CVM") Instruction 598/2018. It is distributed only for information purposes to clients of UBS Brasil Administradora de Valores Mobiliários Ltda. and/or of UBS Consenso Investimentos Ltda., entities regulated by CVM. Canada: In Canada, this publication is distributed to clients of UBS Wealth Management Canada by UBS Investment Management Canada Inc.. China: This report is prepared by UBS Switzerland AG or its offshore subsidiary or affiliate (collectively as "UBS Offshore"). UBS Offshore is an entity incorporated out of China and is not licensed, supervised or regulated in China to carry out banking or securities business. The recipient should not contact the analysts or UBS Offshore which produced this report for advice as they are not licensed to provide securities investment advice in China. UBS Investment Bank (including Research) has its own wholly independent research and views which at times may vary from the views of UBS Global Wealth Management. This report shall not be regarded as providing specific securities related analysis. The recipient should not use this document or otherwise rely on any of the information contained in this report in making investment decisions and UBS takes no responsibility in this regard. Czech Republic: UBS is not a licensed bank in the Czech Republic and thus is not allowed to provide regulated banking or investment services in the Czech Republic. Please notify UBS if you do not wish to receive any further correspondence. Denmark: This publication is not intended to constitute a public offer under Danish law. It is distributed only for information purposes to clients of UBS Europe SE, Denmark Branch, filial af UBS Europe SE, with place of business at Sankt Annae Plads 13, 1250 Copenhagen, Denmark, registered with the Danish Commerce and Companies Agency, under No. 38 17 24 33. UBS Europe SE, Denmark Branch, filial af UBS Europe SE is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Danish Financial Supervisory Authority (Finanstilsynet), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. France: This publication is distributed by UBS (France) S.A., French "société anonyme" with share capital of € 132.975.556, 69, boulevard Haussmann F-75008 Paris, R.C.S. Paris B 421.255 670, to its clients and prospects. UBS (France) S.A. is a provider of investment services duly authorized according to the terms of the "Code Monétaire et Financier", regulated by French banking and financial authorities as the "Autorité de Contrôle Prudentiel et de Résolution". Germany: This publication is not intended to constitute a public offer under German law. It is distributed only for information purposes to clients of UBS Europe SE, Germany, with place of business at Bockenheimer Landstrasse 2-4, 60306 Frankfurt am Main. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the European Central Bank ("ECB"), and supervised by the ECB, the German Central Bank (Deutsche Bundesbank) and the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), to which this publication has not been submitted for approval. Greece: UBS Switzerland AG and its affiliates (UBS) are not licensed as a bank or financial institution under Greek legislation and do not provide banking and financial services in Greece. Consequently, UBS provides such services from branches outside of Greece, only. This document may not be considered as a public offering made or to be made to residents of Greece. Hong Kong: This publication is distributed to clients of UBS AG Hong Kong Branch by UBS AG Hong Kong Branch, a licensed bank under the Hong Kong Banking Ordinance and a registered institution under the Securities and Futures Ordinance. UBS AG Hong Kong Branch is incorporated in Switzerland with limited liability. India: UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Number INZ000259830; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securitiesrelated services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html Indonesia, Malaysia, Philippines, Thailand: This material was provided to you as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the material erroneously, UBS asks that you kindly destroy/delete it and inform UBS immediately. Any and all advice provided and/or trades executed by UBS pursuant to the material will only have been provided upon your specific request or executed upon your specific instructions, as the case may be, and may be deemed as such by UBS and you. The material may not have been reviewed. approved, disapproved or endorsed by any financial or regulatory authority in your jurisdiction. The relevant investments will be subject to restrictions and obligations on transfer as set forth in the material, and by receiving the material you undertake to comply fully with such restrictions and obligations. You should carefully study and ensure that you understand and exercise due care and discretion in considering your investment objective, risk appetite and personal circumstances against the risk of the investment. You are advised to seek independent professional advice in case of doubt. Israel: UBS is a premier global financial firm offering wealth management, asset management and investment banking services from its headquarters in Switzerland and its operations in over 50 countries worldwide to individual, corporate and institutional investors. In Israel, UBS Switzerland AG is registered as Foreign Dealer in cooperation with UBS Wealth Management Israel Ltd., a wholly owned UBS subsidiary. UBS Wealth Management Israel Ltd. is a Portfolio Manager licensee which engages also in Investment Marketing and is regulated by the Israel Securities Authority. This publication is intended for information only and is not intended as an offer to buy or solicitation of an offer. Furthermore, this publication is not intended as an investment advice and/or investment marketing and is not replacing any investment advice and/or investment marketing provided by the relevant licensee which is adjusted to each person needs. The word "advice" and/or any of its derivatives shall be read and construed in conjunction with the definition of the term "investment marketing" as defined under the Israeli Regulation of Investment Advice, Investment Marketing and Portfolio Management Law, 1995. Italy: This publication is not intended to constitute a public offer under Italian law. It is distributed only for information purposes to clients of UBS Europe SE, Succursale Italia, with place of business at Via del Vecchio Politecnico, 3-20121 Milano. UBS Europe SE, Succursale Italia is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Bank of Italy (Banca d'Italia) and the Italian Financial Markets Supervisory Authority (CONSOB - Commissione Nazionale per le Società e la Borsa), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. Jersey: UBS AG, Jersey Branch, is regulated and authorized by the Jersey Financial Services Commission for the conduct of banking, funds and investment business. Where services are provided from outside Jersey, they will not be covered by the Jersey regulatory regime. UBS AG, Jersey Branch is a branch of UBS AG a public company limited by shares, incorporated in Switzerland whose registered offices are at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH 8001 Zurich. UBS AG, Jersey Branch's principal place business is 1, IFC Jersey, St Helier, Jersey, JE2 3BX. Luxembourg: This publication is not intended to constitute a public offer under Luxembourg law. It is distributed only for information purposes to clients of UBS Europe SE, Luxembourg Branch, with place of business at 33A, Avenue J. F. Kennedy, L-1855 Luxembourg. UBS Europe SE, Luxembourg Branch is subject to the joint supervision of the European Central Bank ("ECB"), the German Central bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Luxembourg supervisory authority (Commission de Surveillance du Secteur Financier), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. Mexico: This information is distributed by UBS Asesores México, S.A. de C.V. ("UBS Asesores"), an affiliate of UBS Switzerland AG, incorporated as a non-independent investment advisor under the Securities Market Law due to the relation with a Foreign Bank. UBS Asesores is a regulated entity and it is subject to the supervision of the Mexican Banking and Securities Commission ("CNBV"), which exclusively regulates UBS Asesores regarding the rendering of portfolio management, as well as on securities investment advisory services, analysis and issuance of individual investment recommendations, so that the CNBV has no surveillance faculties nor may have over any other service provided by UBS Asesores. UBS Asesores is registered before CNBV under Registry number 30060. You are being provided with this UBS publication or material because you have indicated to UBS Assores that you are a Sophisticated Qualified Investor located in Mexico. The compensation of the analyst(s) who prepared this report is determined exclusively by research management and senior management of any entity of UBS Group to which such analyst(s) render services. Nigeria: UBS Switzerland AG and its affiliates (UBS) are not licensed, supervised or regulated in Nigeria by the Central Bank of Nigeria or the Nigerian Securities and Exchange Commission and do not undertake banking or investment business activities in Nigeria. Portugal: UBS Switzerland AG is not licensed to conduct banking and financial activities in Portugal nor is UBS Switzerland AG supervised by the portuguese regulators (Bank of Portugal "Banco de Portugal" and Portuguese Securities Exchange Commission "Comissão do Mercado de Valores Mobiliários"). Singapore: This material was provided to you as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the material erroneously, UBS asks that you kindly destroy/delete it and inform UBS immediately. Clients of UBS AG Singapore branch are asked to please contact UBS AG Singapore branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or report. Spain: This publication is not intended to constitute a public offer under Spanish law. It is distributed only for information purposes to clients of UBS Europe SE, Sucursal en España, with place of business at Calle María de Molina 4, C.P. 28006, Madrid. UBS Europe SE, Sucursal en España is subject to the joint supervision of the European Central Bank ("ECB"), the German Central bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Spanish supervisory authority (Banco de España), to which this publication has not been submitted for approval. Additionally it is authorized to provide investment services on securities and financial instruments, regarding which it is supervised by the Comisión Nacional del Mercado de Valores as well. UBS Europe SE, Sucursal en España is a branch of UBS Europe SE, a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. Sweden: This publication is not intended to constitute a public offer under Swedish law. It is distributed only for information purposes to clients of UBS Europe SE, Sweden Bankfilial, with place of business at Regeringsgatan 38, 11153 Stockholm, Sweden, registered with the Swedish Companies Registration Office under Reg. No 516406-1011. UBS Europe SE, Sweden Bankfilial is subject to the joint supervision of the European Central Bank ("ECB"), the German Central bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht). as well as of the Swedish supervisory authority (Finansinspektionen), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. Taiwan: This material is provided by UBS AG, Taipei Branch in accordance with laws of Taiwan, in agreement with or at the request of clients/prospects. UAE: UBS is not licensed in the UAE by the Central Bank of UAE or by the Securities & Commodities Authority. The UBS AG Dubai Branch is licensed in the DIFC by the Dubai Financial Services Authority as an authorised firm. UK: This document is issued by UBS Wealth Management, a division of UBS AG which is authorised and regulated by the Financial Market Supervisory Authority in Switzerland. In the United Kingdom, UBS AG is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of regulation by the Prudential Regulation Authority are available from us on request. A member of the London Stock Exchange. This publication is distributed to retail clients of UBS Wealth Management. Version 05/2019. CIO82652744

© UBS 2019.The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.